Clinical efficacy and neuroprotective effects of brimonidine in the management of glaucoma and ocular hypertension

Clinical Ophthalmology

Volumn 3, Issue 1, 2009, Pages 117-122

  Galanopoulos, Anna ^a   Goldberg, Ivan ^b,c,d  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c SYDNEY EYE HOSPITAL   (Australia)

^d Eye Associates   (Australia)

Author keywords

Brimonidine; Clinical effectiveness; Neuroprotection; Tolerability

Indexed keywords

APRACLONIDINE; BENZALKONIUM CHLORIDE; BETAXOLOL; BRIMONIDINE; BRIMONIDINE PLUS TIMOLOL; CHLORINE DIOXIDE; CLONIDINE; DORZOLAMIDE; DORZOLAMIDE PLUS TIMOLOL; LATANOPROST; PURITE; TIMOLOL; UNCLASSIFIED DRUG;

ALLERGIC REACTION; ALLERGY; APNEA; ARGON LASER; BLURRED VISION; BRADYCARDIA; BURNING SENSATION; CARDIOTOXICITY; CLINICAL TRIAL; COMA; CONCENTRATION RESPONSE; CONJUNCTIVITIS; DEGENERATIVE DISEASE; DROWSINESS; DRUG CONTRAINDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG PENETRATION; DRUG SAFETY; DRUG TOLERABILITY; EYE ALLERGY; EYE DISCOMFORT; EYE IRRITATION; EYE TOXICITY; EYELID RETRACTION; FATIGUE; GLAUCOMA; HEADACHE; HUMAN; HYPEREMIA; HYPOTENSION; INTRAOCULAR HYPERTENSION; LETHARGY; LUNG TOXICITY; MYDRIASIS; NEUROPROTECTION; OPTIC NERVE DISEASE; PATHOPHYSIOLOGY; PATIENT SATISFACTION; RETINA INJURY; REVIEW; SEDATION; SIDE EFFECT; SOMNOLENCE; TRABECULOPLASTY; XEROSTOMIA;

EID: 77950354281     PISSN: 11775467     EISSN: 11775483     Source Type: Journal    
DOI: None     Document Type: Review

References (60)

1. Tunnel vision : The Economic Impact of Primary Open Angle Glaucoma - A Dynamic Economic Model. Centre for Eye Research Australia. 2008.
2. Mitchell P, Smith W, Attebo K, et al. Prevalence of open-angle glaucoma in Australia. The Blue Mountains Eye Study. Ophthalmology. 1996;103(10):1661-9.
3. Klein BE, Klein R, Spinsel WE, et al. Prevalence of glaucoma. The Beaver Dam Eye Study. Ophthalmology. 1992;99:1499-504.
4. The AGIS investigators. The Advanced Glaucoma Intervention Study (AGIS):7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalol. 2000;130:429-40.
5. Neuroprotection and Glaucoma; Current Concepts. 2002 Oxford Institiute.
6. Toris CB, Camras CB, Yablonski ME. Acute versus chronic effects of brimonidine on aqueous humor dynamics in ocular hypertensive patients. Am J Ophthalmol. 1999;128(1):8-14.
7. Cantor LB. The evolving pharmacotherapeutic pro. le of brimonidine, an alpha2-adrenergic agonist, after four years of continuous use. Expert Opin Pharmacother. 2000;1:815-34.
8. Walters TR. Development and use of brimonidine in treating acute and chronic elevations of intraocular pressure, a review of safety, efficacy, dose response and dosing studies. Surv Ophthalmol. 1996;41:S19-S26.
9. Weinreb RN, Levin LA. Is neuroprotection a viable therapy for glaucoma? Arch Ophthalmol. 1999;117:1540-4.
10. Wheeler LA, Gil DW, WoldeMussie E. Role of alph2adrenergic receptors in neuroprotection and glaucoma. Surv Ophthalmol. 2001;45(Suppl 3):S290-294.
11. Bylund DB, Chacko DM. Characterization of alpha2 adrenergic receptor subtypes in human ocular tissue. Ivest Ophthalmol Vis Sci. 1999;40:2299-306,
12. Burke J, Manlapaz C, Kharlamb A, et al. Therapeutic use of a2-adrenoreceptor agonists in glaucoma. In: Lanier SM, Limbird LE (eds). Alpha-Adrenergic Receptors Structure, Function and Therapeutic Implications. Reading, UK, Harwood Academic Publishers; 1996. pp 179-87.
13. Kent A, Nussdorf J, David R, et al. Vitreous concentrations of topically applied brimonidine tartrate 0.2%. Ophthalmology. 2001;108:784-7.
14. WoldeMussie E, Ruiz G, Wijono M, Wheeler LA. Neuroprotection of retinal ganglion cells by brimonidine in rats with laser- induced chronic ocular hypertension. Invest Ophthalmol Vis Sci. 2001:42:2849-55.
15. Hernandez M, Urcola JH, Vecino E. Retinal ganglion cell neuroprortection in a rat model of glaucoma following brimonidine, latanoprost or combined treatments. Exp Eye Res. 2008;86:798-806.
16. Wheeler LA, Lai R, WolenMussie E. From the lab to the clinic: activation of an alpha-2 agonist pathway is neuroprtoective in models of retinal and optic nerve injury. Eur J Ophthalmol. 1999;9(Suppl 1):S17-21.
17. Donello JE, Padillo EU, Webster ML, et al. Alpha(2)-adrenoceptoragonists inhibit vitreal glutamate and aspartate accumulation and preserve retinal function after transient ischaemia. J Pharmacol Exp Ther. 2001;296:216-23.
18. Wheeler LA, Tatton NA, Elstner M, et al. Alpha-2 adrenergic receptor activation by brimondine reduces neuronal apoptosis through Akt (ptrotien Kinase B) dependent new synthesis of BCL-2. Invest Opthalmol Vis Sci. 2001;42:S411.
19. Aung T, Oen FT, Wong HT, et al. Randomised controlled trial comparing the effect of brimonidine and timolol on visual field loss after acute primary angle closure. Br J Ophthalmol. 2004;88(1):88-94.
20. Ferencz JR, Gilady G, Harel O et al. Topical brimonidine reduces collateral damage caused by laser photocoagulation for choroidal neovascularization. Graefes Arch Clin Exp Ophthalmol. 2005;243:877-80.
21. Tsai JC, Chang HW: Comparison of the effects of brimonidine 0.2% and timolo 0.5% on retinal nerve fiber layer thickness in ocular hypertensive patients: a prospective, unmasked study. J Ocul Pharmacol Ther. 2005 Dec;21(6):474-82.
22. Gandolfi SA, Sangermani C, Cimino L. et al. Is there a non IOP- related effect of brimonidine on visual field progression in human glaucoma? IOVS, 2004(45) ARVO E-abstract 2298.
23. Evans DW, Hosking SL, Gherghel D, Barlett JD. Contrast sensitivity improves after brimonidine therapy in primary open angle glaucoma: a case for neuroprotection. Br J Ophthalmol. 2003;87(12):1463-5.
24. Krupin T, Liebmann JM, Greenfield DS, Rosenberg LF, Ritch R et al. The Low-pressure Glaucoma Treatment Study (LoGTS) Study design and baseline characteristics of enrolled patients. Ophthalmology. 2005;112:376-85.
25. Krupin T. Special consideration in low tension glaucoma. Can J Ophthalmol. 2007;42:414-7
26. Market Share Data for Australia , from IMS June 2008.
27. Katz LJ. For the Brimonidine Study Groups 1 and 2. Twice-daily brimonidine tartrate 0.2% vs timolol 0.5%: 1 year results in glaucoma patients. Am J Ophthalmol. 1999;127:20-6.
28. Schuman JS, Horwitz B Choplin NT, et al. A 1-year study of brimonidine twice daily in glaucoma and ocular hypertension. A controlled, randomized, multicenter clinical trial. Arch Ophthalmol. 1997;115:847-52.
29. LeBlanc RP; for the Brimonidine Study Group 2. Twelve-month results of an ongoing randomized trial comparing brimonidine tartrate 0.2% and timolol given twice daily in patients with glaucoma or ocular hypertension. Ophthalmology. 1998;105:1960-7.
30. Melamed S, David R; for the Brionidine Study group 2. Ongoing clinical assessment of the safety profile and efficacy of brimonidine compared with timolol: three year results. Clin Ther. 2000;22:103-11.
31. Cantor LB. The evolving pharmacotherapeutic profile of brimonidine, an alpha 2-adrenergic agonist, after for years of continuous use. Exp Opin Pharmcother. 2000;1(4):815-34.
32. Goldberg I, Goldberg H. Betaxlol eye drops. A clinical trial of safety and efficacy. Aust N Z J Ophthalmol. 1995;23:17-24.
33. Goldberg I. The safety of topical beta-blockers in glaucoma treatment. Med J. Aust 1996;164:49-49.
34. Javitt J, Goldberg I. For the Brimonidine Outcomes Study Group 2. Comparison of the clinical success rates and quality of life of brimonidine tartrate 0.2% and betaxolol 0.25% suspension in patients with open-angle glaucoma and ocular hypertension. J Glaucoma. 2000;9:398-408.
35. Serle JB. A comparison of the safety and efficacy of twice daily brimonidine 0.2% versus Betaxolol 0.25% in subjects with elevated intraocular pressure. Surv Ophthalmol. 1996;41(9 suppl 1):S39-47.
36. Hodge WG, Lachaine J, Steffensen I. et al. The efficacy and harm of prostaglandin analogues for the IOP reduction in glaucoma patients compared to dorzolamide and brimonidine: a systematic review. Br J Ophthalmol. 2008;92:7-12.
37. Whitson JT, Henry C, Hughes B, et al. Comparison of the safety and ef. cacy of dorzolamide 2% and brimonidine 0.2% in patients with glaucoma or ocular hypertension. J Glaucoma. 2004;13:168-73.
38. Stewart WC, Sharpe ED, Harbin Jr TS, et al. Brimonidine 0.2% versus dorzolamide 2% each given three times daily to reduce intraocularpressure. Am J Opthalmol. 2001;29:723-7.
39. Sharpe ED, Day DG, Beischel CJ, et al. Brimonidine purite 0.15% versus dorzolamide 2% each given twice daily to reduce intraocular pressure in subjects with open angle glaucoma or ocular hypertension. Br J Ophthalmol. 2004;88:953-6.
40. Simmons ST. Efficacy of brimonidine 0.2% and dorzolamide 2% as adjunctive therapy to beta-blockers in adult patients with glaucoma or ocular hypertension. Clin Ther. 2001;23:604-19.
41. Lee DA, Gornbein JA. Effectiveness and safety of brimonidine as adjunctive therapy for patients with elevated intraocular pressure in a large, open label community trial. J Glaucoma. 2001;10:220-6.
42. Konstas AG, Karabatsas CH, Lallos N, et al. 24-hour intraocular pressures with brimonidine purite versus dorzolamide added to latanoprost in primary open-angle glaucoma subjects. Ophthalmology. 2005;112:603-8.
43. Sherwood MB, Craven ER, Chou C et al. Twice-daily 0.2% brimonidine-0.5% timolol . xed-combination therapy vs monotherapy with timolol or brimonidine in patients with glaucoma or ocular hypertension: a 12-month randomized trial. Arch Ophthlmol. 2006;124:1230-8.
44. Choudri S, Wand M, Shields MB. A Comparison of dorzolamide-timolol combination versus the concomitant drugs. Am J Opthalmol. 200;130:832-3.
45. Everitt DE, Avorn J. Systemic effects of medications used to treat glaucoma. Ann Int Med. 1990;112:120-5.
46. Cantor LB, Hoop J, Katz LJ, et al. For the Alphagan/Betaxolol Clinical Success Study Group. Comparison of the clinical success and quality-of-life impact of brimonidine 0.2% and betaxolol 0.25% suspension in patients with elevated intraocular pressure. Clin Ther. 2001;23(7):1032-9.
47. Thompson CD, MacDonald TL, Garst ME, et al. Mechanisms of adrenergic agonist induced allergy:bioactivation and antigen formation. Exp Eye Res. 1997;64(5):767-73.
48. Abelson MB, Chapin M, Batoosingh A, et al. A retrospective examination of drug-induced allergy to Alphagan and a proposal for a new reporting system. Invest Opthalmol Vis Sci. 1999;40(4):S515. Abstract 2718.
49. Manni G, Centofanti M, Sacchetti M, et al. Demographic and clinical factors associated with the development of alphagan induced allergy. J Glaucoma. 2004;13(2):163-7.
50. Berdy GJ, Abelson MB, Smith IM, George MA. Preservative-free artificial tear preparations. Assessment of corneal epithelial toxic effects. Arch Ophthalmol. 1992;110:528-32.
51. Noecker R. Effects of common ophthalmic preservatives on ocular health. Adv Ther. 2001;18:5.
52. Katz LJ. Twelve-month evaluation of brimonidine-purite versus brimonidine in patients with glaucoma or ocular hypertension. J Glaucoma. 2002;11:119-26.
53. Mundorf T, Williams R, Whitcup S et al. A 3 month comparison of efficacy and safety of brimonidine-purite 0.15% and brimonidine 0.2% in patients with glaucoma or ocular hypertension. J Ocular Pharmacol Ther. 2003;19:1.
54. Enyedi LB, Freedman SF. Safety and ef. cacy of brimonidine in children with glaucoma. J AAPOS. 2002;5(5):281-4.
55. Tsai JC, McClure CA, Ramos SE et al. Compliance barriers in glaucoma: A systematic classi. cation. J Glaucoma. 2003;12:393-8.
56. Nordstrom BL, Friedman DS, Mozaffari E et al. Persistence and adherence with topical glaucoma therapy. Am J Ophthalmol. 2005;140:598-606.
57. Motolko MA. Comparison of allergy rates in glaucoma patients receiving brimonidine 0.2% monotherapy versus fixed-combination brimonidine 0.2%-timolol 0.5% therapy. Curr Med Res Opin. 2008 Aug 6. [Epub ahead of print]
58. Chan K, Testa M, McCluskey P. Ocular Comfort of Combination Glaucoma Therapies:Brimonidine 0.2%/Timolol 0.5% Compared with Dorzolamide2%/Timolol 0.5%. J Ocul Pharmacol Ther. 2007;32(4):372-6.
59. Osborne SA, Montgomery DM, Morris D, McKay IC. Alphagan allergy may increase the propensity for multiple eye-drop allergy. Eye. 2005;19:129-37.
60. Alvaroado JA. Reduced ocular allergy with fixed-combination 0.2% brimonidine- 0.5% timolol. Arch Ophthalmol. 2007;125:717.